Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings

@article{Atmaca2002EfficacyOC,
  title={Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings},
  author={M. Atmaca and M. Kuloğlu and E. Tezcan and A. Unal},
  journal={Human Psychopharmacology: Clinical and Experimental},
  year={2002},
  volume={17}
}
The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. Recently, selective serotonin reuptake inhibitors (SSRIs) have been used more frequently. In the present study, the efficacy and side‐effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared. The 71 patients diagnosed with SP according to DSM‐III‐R were randomly assigned to two subgroups; citalopram (n = 36) or… Expand
Comparison of Treatment Adherence between Selective Serotonin Reuptake Inhibitors and Moclobemide in Patients with Social Anxiety Disorder
TLDR
The SSRI group had a longer treatment duration and lower all-cause discontinuation rate than moclobemide and therefore, could predict better treatment adherence with the SSRIs in the treatment of SAD. Expand
Resistant social anxiety disorder response to Escitalopram
TLDR
Escitalopram has a role in the treatment of resistant SAD, especially in view of the favourable tolerability profile observed in the patients, and controlled studies are required to further investigate these findings. Expand
Pharmacotherapy for social anxiety disorder
TLDR
Medication appears effective in treating SP over the short term (particularly amongst the SSRIs), and the long term, and the possibility of publication bias has to be acknowledged. Expand
Current management of obsessive and phobic states
TLDR
The clinical and psychological features likely to characterize patients refractory to treatment for obsessive-compulsive disorder are described, with the aim of highlighting the need for greater attention to more patient-oriented management of the disease. Expand
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
TLDR
SSRI/clomipramine in combination with CBT/ERP is associated with the optimal response compared to each treatment alone or to other treatments, and the role of pharmacogenomics could become preponderant in the coming years. Expand
Social Anxiety Disorder
TLDR
Present consensus supports the use of SSRIs as the first-line treatment in generalised SAD, partly because of established short-and long-term efficacy in this disorder, evidence for safety and tolerability, and ability to treat co-morbid conditions. Expand
Pharmacotherapy for social anxiety disorder: a systematic review
TLDR
Taken together, trials of selective serotonin reuptake inhibitors and serotonin–norepinephrine reptake inhibitors provide the largest evidence base for agents that are both effective and well tolerated. Expand
Clinical Practice and Epidemiology in Mental Health
Background: Social Anxiety Disorder (SAD) is a common disorder and its high prevalence and lifelong chronicity are such that it represents a substantial public health problem. The observation thatExpand
Social Anxiety Disorder - A Review of Pharmacological Treatments
Social anxiety disorder (social phobia, SAnD) is a chronic, impairing disorder characterised by embarrassment and fear relat- ing to public scrutiny and social performance. In its generalised form itExpand
Pharmacotherapy for social anxiety disorder (SAnD).
TLDR
The SSRIs were the only medication proving effective in reducing relapse based on moderate-quality evidence, and this systematic review is an update of an earlier review of pharmacotherapy of SAnD. Expand
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia.
TLDR
Citalopram appears to be effective in the treatment of social phobia and the role of serotonin in socialphobia deserves further study. Expand
Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study
TLDR
After 12 weeks of treatment the brofaromine group had significantly higher total scores on the LSAS than an age‐ and gender‐matched group of healthy controls and improved further during 9‐month follow‐up treatment period, whereas 60% of the placebo responders who continued long‐term treatment relapsed. Expand
Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
TLDR
Fluvoxamine is efficacious in the pharmacologic management of serious forms of social phobia and resulted in significantly greater decreases in measures of psychosocial disability than did placebo. Expand
Placebo-controlled trial of moclobemide in social phobia.
TLDR
Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small. Expand
Moclobemide in social phobia: a controlled dose-response trial.
TLDR
In this dose-response trial, moclobemide did not demonstrate efficacy at 12 weeks, and some other controlled studies have found moclOBemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Expand
Social phobia: long‐term treatment outcome and prediction of response - a moclobemide study
TLDR
Severe social phobia can be successfully treated in the long-term but many patients may need medication or psychotherapy for many years, and complications such as alcohol abuse make treatment difficult. Expand
Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
TLDR
The findings are consistent with the clinical efficacy for the treatment of social phobia andSide effects more common with brofaromine than placebo included insomnia, dizziness, dry mouth, anorexia, tinnitus, and tremor. Expand
Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine.
TLDR
After eight weeks, both active drugs-phenelzine somewhat more than moclobemide--were clinically and statistically significantly more effective than placebo, as assessed by rating scales. Expand
Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
TLDR
Paroxetine is an effective treatment for patients with generalized social phobia and short-term treatment results in substantial and clinically meaningful reductions in symptoms and disability. Expand
The long-term treatment of social phobia with moclobemide.
Patients meeting the social phobia criteria of the revised third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) on the DSM-III-R Structured Clinical Interview (n =Expand
...
1
2
3
...